Trevi Therapeutics, Inc. (TRVI) saw its stock price soar by 5.27% during intraday trading on Friday, reflecting a significant positive market reaction.
The surge appears to be driven by bullish analyst sentiment, specifically after Stifel raised its price target for the company from $18 to $30. This substantial increase in the target price indicates heightened optimism regarding the company's future financial performance and growth prospects.
Other analysts have also recently provided insights on Trevi Therapeutics, contributing to the positive sentiment in the healthcare sector surrounding the stock.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments